Agenda – Day 3

In January 2016, Jennifer(Yuyao) Jiang took the new role as Audit Director in Internal Audit Services Department(IAS), responsible for Commercial Compliance audits to 12 marketing companies and covering 20 countries in the Asia Pacific. It is her responsibility to strategically set audit plan to marketing companies depending on types of risks, maturity of the compliance framework and business model in individual market / clusters and she has oversight to lead and support audit to be delivered in the region and global with high quality. She previously worked in AZ China Compliance team where she investigated Whistle-Blower cases and was project lead of one data-driven dashboard to monitor Field Force expenditure and high risk employee / vendors, business partner to multi-channels to customize the process and controls within the global compliance framework. Before joining AZ, Jennifer was a statutory auditor in KPMG for 9 years.

Albert van Maaren is Regional Compliance Officer Healthcare APAC (including China and Japan) for Merck KGaA. Albert has over 20 years of experience in the pharmaceutical field, including regulatory affairs, pharmacovigilance, quality assurance, market access, compliance as Pharmaceutical Affairs Director of the Netherlands and Belgium.

Prior to his regional role in Singapore, Albert was also dedicated compliance officer for the Benelux countries and Portugal.

Pete Wu currently takes role as Country Chief Compliance Officer of Novartis Group (China). In this position, Pete is responsible for enabling and driving ethical business conduct in China through effective implementation of I&C programs across divisions and for continuously building a best-in-class I&C function. Pete joined Novartis in April 2009 as Head of Sales for Oncology BU China and was appointed Oncology GM for Taiwan in 2012. Prior to Novartis, Pete worked in a number of multinational companies in marketing and commercial leadership roles in the U.S. and Asia region.

Supervisory Special Agent George McEachern has worked in law enforcement since 1995 and entered on duty with the FBI in 2005. Supervisory Special Agent McEachern is an FBI certified subject matter expert in international corruption and has served in Tampa, Boston, and the Washington Field Office.

In 2013, Supervisory Special Agent McEachern was selected to the FBI’s International Corruption Unit where he managed the FBI’s Foreign Corrupt Practices Act (FCPA) global investigations program and helped architect the FBI International Corruption Squads based in Washington, Los Angeles, New York, Miami, Houston, San Francisco, Boston and New Orleans.

Currently, Supervisory Special Agent McEachern supervises the Washington Field Office International Corruption Squad with a focus on FCPA, International Money Laundering, Kleptocracy and Antitrust investigations. Supervisory Special Agent McEachern is a Certified Fraud Examiner (CFE), Certified Anti-Money Laundering Specialist (CAMS), Certified FBI Computer Response Team (CART) Technician and Authorized FBI Digital Extraction Technician (DExT).

Keith Korenchuk counsels and advises global companies on regulatory and compliance matters worldwide, with a focus on compliance program effectiveness, compliance program implementation, operations and evaluation, and related regulatory counseling and advice. He works in a wide variety of industries and sectors including consumer products, electronics, energy, financial services, life sciences, medical device, pharmaceutical, and technology.

Since 2001, Mr. Korenchuk has been included in The Best Lawyers in America. He has developed, led, and implemented “hands-on” educational and healthcare programs that provide pharmaceuticals and healthcare services, teachers, school supplies, library resources, and computers to indigenous communities in South America for the past 12 years.

Luca Genovese holds an Advanced Master in International Development from the Radboud University of Nijmegen, where amongst other topics he studied accountability frameworks for companies operating in development cooperation. At the Access to Medicine Foundation, Luca leads the research areas of General Access to Medicine Management and Market Influence & Compliance. After gaining experience as free-lance journalist in Italy, Luca worked in Congo on projects related to microcredit and rural development, prior to joining the UN World Food Programme in Burkina Faso. He has also worked as business analyst for a commodity trading company in Rotterdam. Before joining the Access to Medicine Foundation, Luca built up expertise on Public-Private Partnerships and Base-of-the-Pyramid markets while working at the Global Alliance for Improved Nutrition.

Sarah Köchling is the Managing Principal of Shanghai Blossom, a strategic insights, innovation and design consultancy that supports clients to get to breakthrough consumer, market and industry insights and collaboratively transform them into meaningful impact. With over 25 years of experience in China and Asia, including management roles at Procter & Gamble China and J&J Int’l, leading innovation practices at agencies What If and Dragon Rouge and advising China startups, Sarah offers clients an optimal balance of best-practice experience and entrepreneurial savvy. Over the years she and her team have applied their skills across a broad range of consumer and professional categories for many Fortune 500 and global firms.

Howard Lin is Vice President of Ethics & Compliance for Eli Lilly and Company (Lilly) in its China affiliate. Mr. Lin began his career in the Life Sciences industry with Lilly in 1999. His work has spanned multiple therapeutic areas (diabetes, bone/muscle/joint, neuroscience, animal health) and multiple geographies (US, China, Asia-Pacific), with the bulk of his experiences in sales and marketing. Since 2010, Mr. Lin has been based in Asia, and has focused primarily on evolving the field of Ethics & Compliance both within Lilly and in the industry.